KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Charles River Laboratories International (CRL) Shares Repurchased (2016 - 2025)

Charles River Laboratories International has reported Shares Repurchased over the past 17 years, most recently at $96000.0 for Q4 2025.

For Q4 2025, Shares Repurchased fell 22.58% year-over-year to $96000.0; the TTM value through Dec 2025 reached $360.7 million, up 202.64%, while the annual FY2025 figure was $360.7 million, 202.64% up from the prior year.
Shares Repurchased for Q4 2025 was $96000.0 at Charles River Laboratories International, up from $93000.0 in the prior quarter.
Over five years, Shares Repurchased peaked at $353.1 million in Q1 2025 and troughed at $24000.0 in Q3 2022.
A 5-year average of $29.2 million and a median of $4.4 million in 2021 define the central range for Shares Repurchased.
Biggest five-year swings in Shares Repurchased: soared 265126.32% in 2024 and later crashed 99.91% in 2025.
Year by year, Shares Repurchased stood at $267000.0 in 2021, then plummeted by 40.45% to $159000.0 in 2022, then fell by 12.58% to $139000.0 in 2023, then dropped by 10.79% to $124000.0 in 2024, then dropped by 22.58% to $96000.0 in 2025.
Business Quant data shows Shares Repurchased for CRL at $96000.0 in Q4 2025, $93000.0 in Q3 2025, and $7.4 million in Q2 2025.